|Bid||109.27 x 1000|
|Ask||109.99 x 1000|
|Day's Range||107.94 - 109.47|
|52 Week Range||93.88 - 117.10|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||49.31|
|Earnings Date||Apr 23, 2020 - Apr 27, 2020|
|Forward Dividend & Yield||0.84 (0.77%)|
|Ex-Dividend Date||Dec 12, 2019|
|1y Target Est||125.78|
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.
Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.
Hill-Rom (HRC) delivered earnings and revenue surprises of 4.63% and -0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Hillrom (NYSE: HRC), today announced financial results for its fiscal first quarter ended December 31, 2019, confirmed its fiscal 2020 revenue guidance and raised the bottom of its adjusted earnings per diluted share guidance range.
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.